Navigation Links
Chrysalis BioTherapeutics, Inc., Receives $1.5m from the National Cancer Institute to Mitigate Radiotherapy-Induced Brain Tissue Damage
Date:9/23/2013

GALVESTON, Texas, Sept. 23, 2013 /PRNewswire/ -- Today, Chrysalis BioTherapeutics, Inc., announced receipt of a $1.5m contract from the National Cancer Institute (NCI) to continue its development of Chrysalin® to mitigate radiotherapy-induced damage to normal brain tissue. Radiotherapy is a primary tool for controlling tumor growth, yet damage to surrounding normal tissues limit the amount of radiation that can be used to kill tumors. Moreover, side-effects of radiotherapy can have long lasting effects on patients especially in the brain where radiation can affect learning, memory and physical functions. 

(Logo: http://photos.prnewswire.com/prnh/20130919/MM83393LOGO)

According to SEER Cancer Statics, nearly one in 161 people will be diagnosed with brain or nervous system cancer during their lifetime. Finding ways to mitigate damage from radiotherapy or restore neural function following radiotherapy may allow more effective cancer treatment to increase survival and improve quality-of-life for survivors.

This project is a collaboration between Chrysalis BioTherapeutics, Inc., Baylor College of Medicine (BCM), and the University of Texas Medical Branch (UTMB). Pre-clinical results indicate that Chrysalin® treatment restores radiation-damaged neural integrity and promotes neurogenesis in the hippocampus. "These effects of Chrysalin® may be very important," said Dr. Mostafa Waleed Gaber, Associate Professor at Baylor College of Medicine and Co-Director of the Small Animal Imaging Facility at Texas Children's Hospital, "especially in children where successful radiotherapy treatment of brain tumors may have life-long effects on cognitive function."

Chrysalin® is a naturally occurring regenerative peptide that is being developed by Chrysalis BioTherapeutics under world-wide license from UTMB to mitigate effects of nuclear radiation and radiotherapy.  "If we can reduce side effects of radiotherapy in the brain and other tissues, we can use more effective radiotherapy protocols to kill tumors, save lives, and improve quality-of-life." said Dr. Darrell Carney, CEO of Chrysalis BioTherapeutics, Inc.

About Chrysalis.   Chrysalis is a privately held early-clinical-stage biopharmaceutical company developing a thrombin peptide drug platform to mitigate effects of radiation, improve tissue regeneration, and treat myocardial and cardiovascular disease.  Chrysalin® was originally developed by Dr. Carney at UTMB and has been tested in human clinical trials (dermal healing and bone fracture repair) with no adverse side effects. For more information on Chrysalis visit http://www.chrysbio.com.

Media Contact: Kira Blackwell, 409-497-4083, kblackwell@chrysbio.com

This research is fully funded by the National Cancer Institute.  For more information on the NCI, visit http://www.cancer.gov/.        


'/>"/>
SOURCE Chrysalis Biotherapeutics, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Northwest Biotherapeutics, Inc. Announces Full Exercise of Over- Allotment Option
2. Caliber and ImmunGene Launch Valor Biotherapeutics, a Joint Venture to Develop Antibody-Interferon Fusion Therapeutics to Treat Cancers
3. Senior Executives of Cytyc Corporation, and Constitution Medical, Inc., Announce the Launch of ATON PARTNERS
4. An Open Letter from Sterling Scott, CEO, GrowLife, Inc., Regarding the DOJ Position Change Regarding Marijuana
5. Signature Therapeutics, Inc., Presents Four Scientific Posters Today at PAINWeek 2013 Meeting
6. Neurotrope, Inc., Announces Reverse Merger and Completion of $21.9 Million Private Offering
7. National coordinated health care and health IT transformation event will be hosted by OCHIN, Inc., the Oregon Medical Association, and Oregon Health Network: The cHealth Innovation Symposium
8. Morning Research: BioCryst Pharma Inc., Questcor Pharma Inc., PDL BioPharma Inc., and Amgen Inc.
9. MELA Sciences, Inc., A Leader In The Fight Against Melanoma, Hosts Symposium At 8th World Congress Of Melanoma
10. Astute Medical, Inc., veranstaltet Symposium aus anlaß des Critical Care Nephrology Kongress
11. Pioneering Medical Technology Company, Optivus Proton Therapy, Inc., Celebrates 20th Anniversary
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/2/2017)... 2, 2017 Diplomat Pharmacy, Inc. (NYSE: ... and Consulting, LLC , and named its founder as ... in Tennessee , will operate under ... EnvoyHealth,s service offerings for health care partners to include ... "In an interoperable world, technology delivers ...
(Date:9/28/2017)... Sept. 28, 2017 Hill-Rom Holdings, Inc. (NYSE: ... conference call and webcast on Friday, November 3, 2017, ... and ending at approximately 8:30 a.m. (CDT) / 9:30 ... company,s 2017 financial performance and guidance for 2018, Hill-Rom ... to enhance operational performance, and long-range financial outlook through ...
(Date:9/25/2017)...  EpiVax, Inc., a leader in the fields ... announced the launch of EpiVax Oncology Inc., a ... cancer vaccines. EpiVax has provided $500,000 in seed ... technologies to the new precision immunotherapy venture. Gad ... as Chief Executive Officer. Gad brings over 25 ...
Breaking Medicine Technology:
(Date:10/13/2017)... ... ... Yisrayl Hawkins, Pastor and Overseer at The House of Yahweh, has released ... understood books in the Holy Scriptures, Revelation. The Book of Revelation paints a picture ... Many have tossed it off as mere rubbish, but Yisrayl Hawkins says that is ...
(Date:10/13/2017)... ... 2017 , ... “The Journey: From the Mountains to the Mission Field”: the ... in the Philippines. “The Journey: From the Mountains to the Mission Field” is the ... She has taught all ages and currently teaches a class of ladies at her ...
(Date:10/12/2017)... CA (PRWEB) , ... October 12, 2017 , ... ... Cheng, are now treating sleep apnea using cutting-edge Oventus O2Vent technology. ... a serious sleep disorder characterized by frequent cessation in breathing. Oral appliances can ...
(Date:10/12/2017)... ... October 12, 2017 , ... IsoComforter, Inc. ( https://isocomforter.com ... the introduction of an innovative new design of the shoulder pad. The shoulder ... maximum comfort while controlling your pain while using cold therapy. By utilizing ice and ...
(Date:10/12/2017)... ... October 12, 2017 , ... ... that we intend to develop to enable prevention of a major side effect ... hearing loss, especially in pediatric patients. For cisplatin, hearing loss is FDA listed ...
Breaking Medicine News(10 mins):